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Serial APRI measurements 
at follow up to monitor for 
potential fibrosis regression
BACKGROUND & AIMS: Hemochromatosis that is associated with variants in the homeostatic iron regulator gene (HFE)
is characterized by intestinal absorption of iron and excessive body and hepatic iron stores; it
can lead to hepatic fibrosis and cirrhosis. Fibrosis has been staged by analysis of liver biopsies,
but non-invasive staging methods are available. We evaluated the ability of aspartate amino-
transferase:platelet ratio index (APRI), the fibrosis-4 (FIB-4) index, and gamma-glutamyl
transferase:platelet ratio (GPR) to assess hepatic fibrosis staging in subjects with HFE-
associated hemochromatosis, using liver biopsy-staged fibrosis as the reference standard.
METHODS: We performed a retrospective, cross-sectional analysis of 181 subjects with HFE-associated
hemochromatosis and hepatic fibrosis staged by biopsy analysis and available serum sam-
ples. We calculated APRI, FIB-4, and GPR at diagnosis for all 181 subjects and following vene-
section therapy in 64 of these subjects (7 subjects had follow-up biopsy analysis). We used area
under the receiver operating characteristic curve (AUROC) analysis to assess the relationships
bAuthors share co-senior authorship.
Abbreviations used in this paper: APRI, aspartate aminotransferase-to-
platelet ratio; AUROC, area under the receiver operator characteristic
curve; CI, confidence interval; FIB-4, fibrosis-4; GPR, gamma-glutamyl
transferase ratio; HFE, homeostatic iron regulator gene; HH, HFE hemo-
chromatosis; ROC, receiver operator characteristic.
© 2021 by the AGA Institute. Published by Elsevier, Inc. This is an open




Clinical Gastroenterology and Hepatology 2020;-:-–-
FLA 5.6.0 DTD  YJCGH57398_proof  5 March 2021  4:46 am  ce CLR
between APRI score, FIB-4 score, and GPR and advanced (F3–F4) fibrosis and to select cut-off
values.
RESULTS: Hepatic fibrosis stage correlated with APRI score (r [ 0.54; P < .0001), FIB-4 score (r [ 0.35;
P < .0001), and GPR (r [ 0.36, P < .0001). An APRI score above 0.44 identified patients with
advanced fibrosis with an AUROC of 0.88, 79.4% sensitivity, 79.4% specificity, and 81% accu-
racy. A FIB-4 score above 1.1 identified patients with advanced fibrosis with an AUROC of 0.86,
80% sensitivity, 80.3% specificity, and 81% accuracy. A GPR above 0.27 identified patients with
advanced fibrosis with an AUROC of 0.76, 67.7% sensitivity, 70.3% specificity, and 69% accu-
racy. APRI score was significantly more accurate than GPR (P [ .05) in detecting advanced
fibrosis; there was no difference between APRI and FIB-4. Venesection treatment was associ-
ated with significant reductions in APRI (P < .0001) and GPR (P < .001), paralleling fibrosis
regression observed in available liver biopsies. Post-venesection APRI identified 87% of sub-
jects with advanced fibrosis that decreased to levels that indicate stage F1–F2 fibrosis.
CONCLUSIONS: In a retrospective study of 181 subjects with HFE-associated hemochromatosis, we found that
APRI and FIB-4 scores identified patients with advanced hepatic fibrosis with 81% accuracy.
APRI scores might also be used to monitor fibrosis regression following venesection.
Keywords: HH; Disease Progression; Respond to Treatment; Blood Test.
Homeostatic iron regulator gene (HFE) hemochro-matosis (HH) is a common genetic disorder of iron
metabolism,1 characterized by dysregulated hepcidin
expression, resulting in increased intestinal absorption of
iron and excessive total body and hepatic iron stores.2–4 In
some individuals advanced fibrosis and cirrhosis may
develop, increasing mortality and morbidity.5 Liver biopsy
has been the gold standard for fibrosis staging in HH pa-
tients, because early identification of advanced hepatic
fibrosis or cirrhosis is crucial in guiding appropriate clinical
management. However, liver biopsies are not without risk,
and the heterogeneousdistribution offibrosis development
may result in an underestimation of the actual staging of
fibrosis. In addition, liver biopsy does not allow for easy,
dynamic, ongoing assessment of fibrosis progression.
There has been a progressive evolution of noninva-
sive modalities for the detection and staging of hepatic
fibrosis in a variety of different chronic liver diseases.
These include ultrasound and elastography-based tech-
nologies, blood test panels, and serum biomarker indices
(for example, aspartate aminotransferase-to-platelet ra-
tio index [APRI], gamma-glutamyl transferase-to-platelet
ratio [GPR], fibrosis-4 [FIB-4]). These serum biomarker
indices have been shown to be useful, easy to perform,
and relatively inexpensive. In addition, these tests can be
repeated frequently, unlike liver biopsies, to provide
ongoing assessment of fibrosis progression. Such
methods for assessing hepatic fibrosis have been vali-
dated in adult patients with viral hepatitis, nonalcoholic
fatty liver disease, human immunodeficiency virus/hep-
atitis B coinfection, as well as in children with cystic
fibrosis–associated liver disease (a condition with a
similar heterogeneous pattern of fibrosis deposition).6–14
However, no large studies have assessed the efficacy of
these biomarkers in HH. Other studies have evaluated
different models in the prediction of advanced fibrosis in
HH. For example, the clinical parameters of serum
ferritin >1000 mg/L, with an elevated aspartate amino-
transferase level and a platelet count >200  109/L,
were shown to predict cirrhosis in the majority of HH
subjects.15 However approximately 30%–64% of pa-
tients with cirrhosis do not fulfill all 3 criteria.15,16 Serum
hyaluronic acid levels >46.5 ng/mL have also been
shown to have high sensitivity and specificity in identi-
fying the presence of cirrhosis in HH patients and
together with serum ferritin level >1000 mg/L obviate
the need for liver biopsy in 60% of patients.16 Although
transient elastography for assessment of fibrosis has
been used in viral hepatitis and nonalcoholic fatty liver
disease,6,7 its use in HH has not been clearly defined.
Magnetic resonance imaging elastography has been
assessed in HH, but as with all forms of elastography,
cost and accessibility can be significant limiting factors.17
Serum biomarker indices such as APRI, FIB-4, and GPR
may offer a more viable alternative because they are
likely to be highly cost-effective and readily available via
liver function tests performed during routine blood
workup at clinic visits for patients with HH.
Therefore, the aim of this study was to assess the
potential of these simple, readily available, and inex-
pensive noninvasive serum biomarker indices (APRI,
GPR, and FIB-4) to predict the stage of fibrosis and
determine cutoff thresholds for the detection of
advanced hepatic fibrosis in a large, well-characterized
cohort of liver biopsy-validated subjects with HH
before and after venesection treatment.
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Methods
Patients
The study subjects were derived from a database of
all HH subjects referred between 1983 and 2013 to the
Royal Brisbane and Women’s Hospital, Australia. Inclu-
sion criteria were met by 181 subjects, requiring com-
plete baseline demographics, total number of
venesections, alcohol consumption, serum biochemistry,
and liver biopsy histologic assessments (with formal
scoring of fibrosis) of subjects to be extracted from the
QIMR Berghofer Medical Research Institute HH database.
The alcohol consumption of subjects in the study was
recorded by using methods by the National Health and
Medical Research Council of Australia, which define one
standard drink as containing 10 g of alcohol (equivalent
to 12.5 mL of pure alcohol). All subjects were confirmed
as being C282Y homozygous on genetic testing. All sub-
jects were routinely offered a liver biopsy as part of
baseline assessment. Venesection treatment was per-
formed weekly until a serum ferritin level <100 mg/L
was achieved. Liver biopsy was also performed in 7
subjects after treatment for clinically indicated reasons.
APRI, GPR, and FIB-4 data were calculated for all study
subjects at the time of liver biopsy before commencing
venesection. These biomarker indices were also calcu-
lated in a subgroup of 64 subjects after completion of
venesection, including 7 patients who underwent a sec-
ond biopsy. Exclusion criteria included age <16 years or
other forms of chronic liver disease (chronic viral hep-
atitis, immune-mediated, metabolic liver diseases), which
were assessed through standard, routine testing and
clinical assessment as previously described.18 Subject
age was defined as the age when the liver biopsy was
performed. All subjects were untreated at the time of
study inclusion. Paraffin-embedded sections were
stained with hematoxylin-eosin and Perls’ Prussian blue
and reviewed by liver histopathologists with expertise in
HH who classified fibrosis stage according to the grading
system of Scheuer: F0, no fibrosis; F1, mild fibrosis with
enlarged portal tracts; F2, moderate periportal and
portal-portal septa but intact architecture; F3, severe
fibrosis with architectural distortion; and F4, cirrhosis
with architectural distortion.19 For the purposes of this
study, subjects with hepatic fibrosis stages F3–F4 were
combined and termed advanced fibrosis. These studies
were approved by the Human Research Ethics Commit-
tees of the Royal Brisbane and Women’s Hospital and the
QIMR Berghofer Medical Research Institute, Brisbane,
Australia, and informed written consent was obtained at
the time of entry into the study.
Statistical Analysis
All data are presented as mean  standard error of
the mean unless otherwise specified. Spearman’s rank
correlation was used to assess associations with
increasing stage of hepatic fibrosis. The Student t test or
analysis of variance was used to analyze differences be-
tween groups. Receiver operator characteristic (ROC)
curve analysis was performed to evaluate the discrimi-
natory capacity of APRI, GPR, and FIB-4 for the diagnosis
of advanced fibrosis and to establish appropriate cutoffs.
In addition, dual cutoff values to demonstrate best ac-
curacy to rule in (specificity >90%) and rule out
(sensitivity >90%) advanced fibrosis were also deter-
mined. The method described by Hanley and McNeil20
was used to compare performance of the ROC curves.
To assess the impact of venesection on APRI, GPR, and
FIB-4 we performed a Wilcoxon signed rank paired t test
on paired patient biomarker indices post-venesection vs
pre-venesection and generated Bland-Altman plots
showing relative fold-change of indices with venesection
for F0–F2 and F3–F4 fibrosis cohorts. To assess the po-
tential clinical utility of post-venesection APRI, GPR, and
FIB-4 in predicting fibrosis regression, logistic regression
was used to model fibrosis stage (dichotomized as mild
fibrosis, F1-F2 and advanced fibrosis, F3–F4) versus
APRI, GPR, or FIB-4 at biopsy. A cutoff value was selected
to maximize the Youden’s index (sensitivity þ speci-
ficity). This cutoff was applied to APRI, GPR, and FIB-4
values determined after venesection (de-ironing) to
predict fibrosis stage. The effect of alcohol consumption
on biomarker indices both at biopsy and after de-ironing
was assessed by using analysis of variance and Tukey-
What You Need to Know
Background
Hemochromatosis that is associated with variants in
the homeostatic iron regulator gene (HFE) is char-
acterized by intestinal absorption of iron and
excessive body and hepatic iron stores; it can lead to
hepatic fibrosis and cirrhosis. Fibrosis has been
staged by analysis of liver biopsies, but noninvasive
staging methods are available.
Findings
This retrospective study of 181 subjects with HFE-
associated hemochromatosis found that amino-
transferase:platelet ratio index (APRI) and fibrosis-4
(FIB-4) scores identify patients with advanced he-
patic fibrosis (stage F3–F4) with 81% accuracy.
Post-venesection APRI identified 87% of subjects
with advanced fibrosis that decreased to levels that
indicate stage F1–F2 fibrosis.
Implications for patient care
APRI and FIB-4 measurements can be used to non-
invasively identify patients with HFE-associated he-
mochromatosis who have advanced hepatic fibrosis.
APRI scores might also be used to monitor fibrosis
regression after venesection.
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Kramer honestly significant difference. Statistical signif-
icance was assigned as P .05. All statistical tests were
conducted by using GraphPad Prism 7 (GraphPad Soft-
ware, San Diego, CA) and JMP Pro (SAS Institute, Cary,
NC).
Results
Baseline characteristics of all subjects are presented
in Supplementary Table 1. Mean age was 42.7  1.1
years for male patients and 46  2.3 years for female
patients. Mean alcohol consumption was 28.5  2.5 g/
day (19.8  3.5 g/day for female patients and 31.7  3.1
g/day for male patients; P ¼ .01). Advanced hepatic
fibrosis was identified in 34 subjects and was more
prevalent in male patients. Mean APRI, GPR, and FIB-4
were significantly higher in those with advanced
fibrosis versus those without (Supplementary Table 1).
ROC curve analysis assessed the discriminant ability of
APRI, GPR, and FIB-4 (Table 1). Comparison of the ROC
curves20 demonstrated significantly higher area under
the ROC curve (AUROC) for APRI versus GPR (P ¼ .05),
but there was no significant difference between APRI and
FIB-4 or between FIB-4 and GPR. Figure 1 shows a sig-
nificant correlation between all 3 biomarkers and
increasing hepatic fibrosis stage (APRI, r ¼ 0.54, P <
.0001; GPR, r ¼ 0.36, P < .0001; FIB-4, r ¼ 0.35, P <
.0001).
Diagnostic Accuracy of Aspartate
Aminotransferase-to-Platelet Ratio Index,
Gamma-Glutamyl Transferase Ratio, and
Fibrosis-4 for the Prediction of Advanced
Fibrosis
The AUROC for APRI was 0.88 (95% confidence in-
terval [CI], 0.81–0.96), providing an optimal threshold
for detection of advanced fibrosis of 0.44 (Figure 2A),
with sensitivity of 79.4%, specificity of 79.3%, and
diagnostic accuracy of 81% (Table 1). Dual cutoff values
were also identified with best accuracy to rule in
advanced fibrosis, APRI 0.59 (specificity 90.3%), and
rule out advanced fibrosis, APRI 0.37 (sensitivity
91.1%) (Table 2). Using the identified cutoff value of
>0.44, 29 of 34 patients (85.3%) with F3–F4 fibrosis
were accurately staged, whereas 21.2% of patients with
F0–F2 fibrosis were staged incorrectly.
The AUROC for GPR was 0.76 (95% CI, 0.67–0.85),
providing an optimal threshold for detection of advanced
fibrosis of 0.27 (Figure 2B), with sensitivity of 67.7%,
specificity of 70.3%, and diagnostic accuracy of 69%
(Table 1). Dual cutoff values were also identified with
best accuracy to rule in advanced fibrosis, GPR 0.57
(specificity 90.3%), and rule out advanced fibrosis, GPR
0.15 (sensitivity 91.2%) (Table 2). Using the identified
cutoff value of >0.27, 23 of 34 patients (67.6%) with
F3–F4 fibrosis were correctly staged, whereas 29.5% of
patients with F0–F2 fibrosis were staged incorrectly.
The AUROC for FIB-4 was 0.86 (95% CI, 0.78–0.95),
providing an optimal threshold for detection of advanced
fibrosis of 1.11 (Figure 2C), with sensitivity of 80%,
specificity of 80.3%, and diagnostic accuracy of 81%
(Table 1). Dual cutoff values were also identified with
best accuracy to rule in advanced fibrosis, FIB-4 1.38
(specificity 90.6%), and rule out advanced fibrosis, FIB-4
0.73 (sensitivity 96.0%) (Table 2). Using the identified
cutoff value of >1.11, 20 of 25 patients (80%) with
F3–F4 fibrosis were correctly staged, whereas 18.9% of
patients with F0–F2 fibrosis were staged incorrectly.
Effect of Venesection on Aspartate
Aminotransferase-to-Platelet Ratio Index,
Gamma-Glutamyl Transferase Ratio, and
Fibrosis-4 and Potential to Monitor Fibrosis
Regression
After venesection therapy (when serum ferritin levels
decreased to <100 mg/L), APRI, GPR, and FIB-4 were
recalculated. The mean ( standard error of the mean)
interval time between the initial (at biopsy) and follow-
up (at de-ironing) assessments was 2.66  0.3 years
(range, 0.03–10.5 years). Therapeutic venesection of 64
HH subjects led to a significant reduction in their APRI (P
< .0001) values (Figure 3A), including in subjects with
F0, F0–F2, or F3–F4 fibrosis (Figure 4). Figure 3B shows
APRI plotted as fold-change after venesection vs APRI
measured at biopsy for F0–F2 vs F3–F4 fibrosis. GPR was
also significantly reduced after venesection (Figure 3A,







(95% CI) PPV (%) NPV (%) % Accuracy Cutoff z value P value
APRI 0.88 (0.81–0.96) 79.4 (63.2–89.7) 79.3 (72–85.1) 79.3 79.4 81 0.44
GPR 0.76 (0.67–0.85) 67.7 (50.8–80.9) 70.3 (62.5–77.1) 69.5 68.5 81 0.27 1.96 .05
FIB-4 0.86 (0.78–0.95) 80 (60.9–91.1) 80.3 (72.6–86.3) 80.2 80.1 69 1.11 1.27 .20
NOTE. 95% confidence intervals in parentheses. P values derived from Hanley-McNeil comparison of z values for GPR and FIB-4 versus APRI.22
APRI, aspartate aminotransferase-to-platelet ratio; AUROC, area under the receiver operator characteristic curve; CI, confidence interval; FIB-4, fibrosis-4; GPR,
gamma-glutamyl transferase-to-platelet ratio; HH, HFE hemochromatosis; NPV, negative predictive value; PPV, positive predictive value.
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P < .001), including in subjects with F0 or F0–F2 fibrosis,
but not in subjects with F3–F4 fibrosis (Supplementary
Figure 1). Figure 3C shows GPR plotted as fold-change
after venesection vs GPR measured at biopsy for F0–F2
vs F3–F4 fibrosis. In contrast, FIB-4 demonstrated no
significant changes with therapy (Figure 3A and D),
including when subjects were analyzed at F0, F0–2, or
F3–F4 fibrosis (not shown).
Because of the significant effect of de-ironing on APRI
and GPR we assessed the potential for post-venesection
APRI and GPR values to predict fibrosis regression
from F3–F4 to mild fibrosis (F1–F2). Logistic regression
of dichotomized fibrosis stage (F1–F2 and F3–F4) versus
APRI at biopsy was highly significant (P < .0001), with
odds ratio of 38.6 (95% CI, 6.3–235.0) per unit change in
APRI for having advanced versus mild fibrosis. The
AUROC was 0.83, with sensitivity of 61.8% and speci-
ficity of 95.9%, using APRI cutoff of 0.785. Applying this
cutoff to the post-venesection APRI values, we found that
of the 15 patients with F3–F4 fibrosis at diagnosis, APRI
values decreased below the cutoff indicative of F1–F2
fibrosis in 13 subjects (87%; 95% CI, 62.1%–96.3%).
Logistic regression of F1–F2 and F3–F4 versus GPR at
biopsy was significant (P ¼ .002), with odds ratio of 2.1
(95% CI, 1.3–3.5) per unit change in GPR for having
advanced versus mild fibrosis. The AUROC was 0.70,
with sensitivity of 82.4% and specificity of 51.0%, using
GPR cutoff of 0.225. Applying this cutoff to the post-
venesection GPR values, we found that of the 15 pa-
tients with F3–F4 fibrosis at diagnosis, GPR values
decreased below the cutoff indicative of F1–F2 fibrosis in
only 6 subjects (40%; 95% CI, 19.8%–64.3%).
The logistic regression of F1–F2 and F3–F4 versus
APRI at biopsy had a significantly higher AUROC versus
GPR at biopsy (0.83 versus 070; difference 0.13, 95% CI,
0.06–0.22; P ¼ .0009). The proportion of F3–F4 patients
Figure 1. There was a significant correlation between increasing hepatic fibrosis stage and (A) APRI (r ¼ 0.54, P < .0001), (B)
GPR (r ¼ 0.36, P < .0001), and (C) FIB-4 (r ¼ 0.35, P < .0001). APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4,
fibrosis 4; GPR, gamma-glutamyl transferase ratio.
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that decreased to F1–F2 levels was significantly higher
for APRI than GPR (87% vs 40.0%; rate ratio ¼ 2.167;
95% CI, 1.13–4.15; likelihood ratio c2, P ¼ .006). Thus,
this result suggests that APRI may be superior to GPR for
the assessment of fibrosis regression after venesection
therapy.
Seven subjects with F3–F4 fibrosis at diagnosis also
had follow-up liver biopsies after de-ironing for clinically
indicated reasons. Hepatic fibrosis regressed 2 F stages
in 5 of 7 patients after venesection but remained un-
changed in 2 patients (P ¼ .06) (Supplementary
Figure 2). There was a significant reduction in APRI
and GPR with de-ironing in these 7 patients but no effect
on FIB-4 (Supplementary Figure 2). There were no as-
sociations between pre- or post-treatment APRI, GPR, or
FIB-4 values and the quantity of iron removed (not
shown).
To assess the influence of alcohol, comparisons be-
tween subjects with no alcohol use, light-moderate (<30
g/day), and heavy (30 g/day) alcohol consumption
were performed. There was no significant effect of
alcohol on APRI, GPR, and FIB-4 when measured at
biopsy (Supplementary Figure 3) or on the fold-change
decrease in these biomarker indices after de-ironing
therapy (Supplementary Figure 4). There were also no
relationships observed between biomarker indices and
iron indices either at biopsy or after venesection (not
shown).
Discussion
This unique, liver biopsy-based study of a well-
characterized cohort of HH subjects before and after
treatment has demonstrated the clinical utility of APRI,
GPR, and FIB-4 for the diagnosis and/or monitoring of
advanced hepatic fibrosis. We found that of these
markers, APRI and FIB-4 demonstrated superior diag-
nostic accuracy in the diagnosis of fibrosis stage. APRI
and GPR values were significantly decreased after
venesection treatment, including when analyzed in sub-
jects with F0, F0–F2, or advanced (F3–F4) fibrosis. In
addition, in a subset of subjects with available post-















Figure 2. (A) APRI, (B) GPR, and (C) FIB-4 values for F3–F4 versus F0–F2 fibrosis with proposed cutoffs for predicting
advanced fibrosis in HH patients (dotted lines). ***P < .01; ****P < .0001. APRI, aspartate aminotransferase-to-platelet ratio
index; FIB-4, fibrosis 4; GPR, gamma-glutamyl transferase ratio; HH, HFE hemochromatosis.
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values reflected fibrosis regression. Finally, we demon-
strated that post-venesection APRI predicted 87% of
subjects with advanced fibrosis decreased to APRI levels
indicative of mild F1–F2 fibrosis. This information has
important clinical implications because it extends the
widespread recognition of the utility of serum bio-
markers in the assessment of advanced fibrosis/cirrhosis
observed in other chronic liver diseases into the man-
agement of subjects with HH.
Our data suggest that optimal cutoff values for these
biomarkers for predicting advanced fibrosis in HH are
lower than those observed in more aggressive conditions
such as viral hepatitis B or C and alcohol-related liver
disease. In previous studies in patients with hepatitis C
virus or alcohol-related liver disease, an APRI cutoff
threshold for advanced fibrosis of 1 was proposed with
demonstrated sensitivity of 35% and specificity of 94%
for the diagnosis of cirrhosis in alcohol-related liver
disease.9,21 If one were to apply an APRI threshold of 1 to
our HH cohort, the sensitivity and specificity of APRI in
HH would be 50% (95% CI, 34.1%–65.9%) and 99.3%
(95% CI, 96.2%–99.9%), respectively. For GPR, at a
threshold of 0.32 (as suggested by Lemoine et al14 in
predicting advanced fibrosis in hepatitis B virus), the
sensitivity and specificity in HH would be 58.8% (95%
CI, 42.2%–73.6%) and 77.2% (95% CI, 69.8%–83.3%),
respectively. With regard to FIB-4, at the lower limit of
1.45 (as suggested by Vallet-Pichard et al11 for advanced
fibrosis in hepatitis C virus), the sensitivity and speci-
ficity in HH would be 64% (95% CI, 44.5%–79.8%) and
92.1% (95% CI, 86.1%–95.7%), respectively. The cutoff
values we defined in HH subjects were more similar to
those found in a study that evaluated the utility of APRI
in subjects with cystic fibrosis–related liver disease
where an APRI 0.462 was able to accurately identify
patients with F3–F4 fibrosis.8 This could be due to HH
being a less inflammatory, more chronic condition
(similar to cystic fibrosis liver disease), where fibrosis
develops in subjects with lower aspartate aminotrans-
ferase levels compared with those observed in viral
hepatitis.22–25
The method described by Beaton et al15 was also
shown to be a reliable predictor of cirrhosis in HH.
However, a significant number of subjects would not
fulfill all 3 criteria.15,16 When applied to our study pop-
ulation, the Beaton model only successfully identified
68% of subjects with cirrhosis (15/22) and only 56% of
those with F3–F4 fibrosis (19/34). In addition, 4 patients
with F0–F1 and 3 patients with F2 fibrosis fulfilled the
Beaton criteria for the prediction of cirrhosis, which was
consistent with data from other studies.16
In our study, APRI, GPR, and FIB-4 demonstrated
significant correlation with hepatic fibrosis stage. Of
particular benefit is these biomarkers can be repeated
regularly to assess potential fibrosis progression or
regression. Previous studies from our group demonstrate
fibrosis regression with venesection.18,26 In a subset of
this cohort, we showed that APRI and GPR were signifi-
cantly decreased with venesection. Monitoring APRI after
venesection could be useful in predicting fibrosis
regression with APRI in 13 of 15 subjects with advanced
fibrosis at diagnosis, decreasing to APRI levels indicative
of mild F1–F2 fibrosis after de-ironing. Both APRI and
GPR reflected biopsy-based changes in fibrosis regres-
sion after venesection, but FIB-4 did not, albeit in 7 pa-
tients where repeat liver biopsy was available. Unlike
other liver diseases, HH is not typically characterized by
significant necroinflammation.22–25 Thus, improvements
in fibrosis indices may be due to decreased iron-induced
hepatocellular damage and, as we propose, may be
reflective of improvements in fibrosis. A previous HH
study, including 23 subjects with advanced fibrosis on
pretreatment biopsy, demonstrated 69% of F3 and 35%
of F4 subjects achieved fibrosis regression 2 F stages
on post-treatment liver biopsy.27 Another HH study
demonstrated that fibrosis stage decreased in 73% of
subjects with F3 fibrosis after treatment, and that
fibrosis reduction to METAVIR F2 was associated with
a major reduction in long-term hepatocellular carcinoma
risk.26 Thus, APRI and potentially GPR present options
for noninvasive monitoring of fibrosis regression after
treatment of HH. Further prospective studies, with
Table 2. Diagnostic Accuracy of APRI, GPR, and FIB-4 Using Optimal Cutoffs to Rule-in and Rule-out Advanced Fibrosis in
HH Subjects
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV (%) NPV (%) P value
APRI <.0001
0.59 70.6 (53.8–83.2) 90.3 (84.5–94.1) 87.9 75.4
0.37 91.1 (77–97) 69.0 (61.0–75.9) 74.6 88.6
GPR <.0001
0.57 38.2 (23.9–55) 90.3 (84.5–94.2) 79.7 59.4
0.15 91.2 (77–97) 31.7 (24.7–40) 57.2 78.3
FIB-4 <.0001
1.38 64 (44.5–79.8) 90.6 (84.2–94.5) 87.2 71.6
0.73 96 (75–98.6) 46.7 (38–55.1) 64.3 92.1
NOTE. 95% confidence intervals are shown in parentheses.
APRI, aspartate aminotransferase-to-platelet ratio; AUROC, area under the receiver operator characteristic curve; CI, confidence interval; GPR, gamma-glutamyl
transferase-to-platelet ratio; FIB-4, fibrosis-4; HH, HFE hemochromatosis; NPV, negative predictive value; PPV, positive predictive value.
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paired liver biopsies, are warranted to confirm and
validate their utility in this setting.
A study by Adhoute et al28 assessed the utility of
Fibroscan and serum-based noninvasive methods of he-
patic fibrosis assessment in 57 subjects with HH versus
46 controls. They found that prevalence of liver stiffness
measurements at a cutoff >7.1 kPa was significantly
higher in HH versus healthy controls. They also found a
correlation between serum biomarkers (including APRI
and FIB-4) with Fibroscan. However, their study did not
include paired liver biopsies to allow for correlation of
noninvasive methods with histology, and thus appro-
priate cutoffs for diagnosis of advanced fibrosis were not
defined. Future studies could assess whether combina-
tions of elastography and biomarkers could provide
better diagnostic accuracy for advanced fibrosis, as
demonstrated in other liver disease etiologies using
elastography and APRI.12,13
We acknowledge limitations of our study including the
retrospective design, which may introduce unintended
bias. Also, the limited numbers of subjects with post-
venesection liver biopsies require caution in interpreta-
tion of the significant decreases observed for APRI and
GPR with biopsy-validated fibrosis regression. However,
this study assesses the performance of 3 separate,
commonly used serum biomarker indices in the diagnosis
of advanced fibrosis in a large, well-characterized cohort
of HH subjects with matched liver biopsies.
Conclusion
This study demonstrates the diagnostic accuracy of
APRI and FIB-4 in the detection of advanced hepatic
fibrosis in HH. Furthermore, APRI and GPR were signif-
icantly reduced in association with venesection therapy.
We propose that APRI measurements may be clinically
useful in monitoring fibrosis regression after treatment.
These readily available biomarkers could be used by
physicians and general practitioners to stratify subjects
for management appropriate to the severity of hepatic















Figure 3. Effect of venesection treatment on APRI, GPR, and FIB-4 in subjects with HH (A) at diagnosis and after de-ironing. (B)
APRI, (C) GPR, and (D) FIB-4 plotted as fold-change after venesection versus when measured at biopsy for F0–F2 (red circles)
versus F3–F4 (blue circles) fibrosis, with line of best fit. (A) Wilcoxon signed rank paired t test on paired patient biomarker
indices values after vs before venesection. ****P < .0001; ***P < .001. (B–D) Bland-Altman plots. APRI, aspartate
aminotransferase-to-platelet ratio index; FIB-4, fibrosis 4; GPR, gamma-glutamyl transferase ratio; HH, HFE
hemochromatosis.
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Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2020.07.052.
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Supplementary Figure 1. Changes in GPR before and after venesection in HH subjects with fibrosis stage at initial diagnosis
of (A) F0, (B) F0–F2, and (C) F3–F4. ***P < .001; **P < .01. APRI, aspartate aminotransferase-to-platelet ratio; GPR, gamma-
glutamyl transferase-to-platelet ratio; HH, HFE hemochromatosis.
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Supplementary Figure 2. Effect of venesection treatment on (A) hepatic fibrosis stage, (B) APRI, (C) GPR, and (D) FIB-4 in 7
HH subjects who had repeat liver biopsies after venesection treatment. *P  .05. APRI, aspartate aminotransferase-to-platelet
ratio; FIB-4, fibrosis-4; GPR, gamma-glutamyl transferase-to-platelet ratio; HH, HFE hemochromatosis.
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Supplementary Figure 3. Effect of alcohol consumption on (A) APRI, (B) GPR, and (C) FIB-4 measured at biopsy. Alcohol
(EtOH) consumption is reported as none, light-moderate (<30 g/day), or heavy (>30 g/day). APRI, aspartate aminotransferase-
to-platelet ratio; FIB-4, fibrosis-4; GPR, gamma-glutamyl transferase-to-platelet ratio.
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Supplementary Figure 4. Effect of alcohol consumption on fold-change decrease in (A) APRI, (B) GPR, and (C) FIB-4 after
venesection. Alcohol (EtOH) consumption is reported as none, light-moderate (<30 g/day), or heavy (>30 g/day). APRI,
aspartate aminotransferase-to-platelet ratio; FIB-4, fibrosis-4; GPR, gamma-glutamyl transferase-to-platelet ratio.
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Supplementary Table 1. Baseline Characteristics of Patients
With HH
Age (y)
Men 42.7  1.1





Men 31.7  3.1







Mean APRI (n ¼ 179)
F0–F2 0.33  0.02
F3–F4 1.25  0.17b
Mean GPR (n ¼ 179)
F0–F2 0.29  0.04
F3–F4 1.16  0.35b
Mean FIB-4 (n ¼ 153)
F0–F2 0.86  0.04
F3–F4 2.52  0.39b
NOTE. Data presented as mean  standard error of the mean or proportions.
APRI, aspartate aminotransferase-to-platelet ratio; FIB-4, Fibrosis-4; GPR,
gamma-glutamyl transferase-to-platelet ratio; HH, HFE hemochromatosis.
aP < .01.
bP < .0001.
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